In addition, although we have analyzed the expression of TFRC in AML cells under many different drug treatments and various clinical scenarios, due to the limited space, our analysis was not sufficiently comprehensive, and a more comprehensive analysis will also become an important area of study for us to further develop targeted drug delivery systems based on HFn nanocages in the future. The gene discussed is TFRC; the disease is acute myeloid leukemia.